This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction Pharmaceutical marketing is entering a new era in 2025, driven by rapid advancements in technology, evolving patient expectations, and tighter compliance demands. In 2025, success is tied to delivering a consistent experience across digital and offline interactions. Disclaimer “This content is not medical advice.
The biotech has confirmed it will not launch the biosimilar until March 2025 however, honouring the terms of its 2020 agreement with Alexion that resolved litigation over the validity of patents covering Soliris (eculizumab) in the US.
Livornese On Friday, March 21, 2025, FDA announced that it was further delaying the effective date for the ACNU final rule until May 27, 2025. Originally, the Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) final rule was to become effective January 27, 2025. By Deborah L.
coli labeled as susceptible in 2010 may be labeled as resistant in 2025. MIC breakpoints can change over time CLSI and other similar bodies change breakpoints periodically based on epidemiological data and other emerging information. This means that the same E. CLSI releases updates on which breakpoints are changing and why.
Award winners by category DELIVERY AND DEVICE INNOVATION SHL Medical for Elexy reusable electromechanical autoinjector ECO-DESIGN WINNER Huhtamaki for Omnilock Ultra PAPER PACKAGING INNOVATION WINNER Mitsubishi Gas Chemical Company for new OXYCAPT Multilayer Plastic Vial PATIENT-CENTRIC DESIGN WINNER UCB Pharma for Bimzelx 160mg 2ml autoinjectors product (..)
In connection with the move away from prescription sales, Akili will reduce its workforce by 40%, which the company projects will extend its runway into the second half of 2025. Akili went public last year and though its prescription sales were slowly increasing, the company’s costs far outstripped its revenues.
The agreement stipulates that certain conditions must be met in the labelling and packaging of these medicinal products. The following new measures are set to be introduced on 1 January 2025. After this date: Under the framework, medicines can have the same packaging and labelling across the UK.
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering the companys 2025 Supply Chain Trends Report, and how they could possibly change in 2026.
billion in 2025 to approximately $174.45 Otherwise, advanced technological features such as “Advanced Recycling PET or Carbon Capture PET” as well as “labelling and sensory tracking systems” offer opportunities too, Towards Packaging asserted. billion by 2033, according to a study published by Towards Packaging.
Currently, AOMs are excluded from Medicare Part D coverage and optional in state Medicaid programs, when used specifically for the treatment of obesity, because they’re labeled as “agents used for weight loss.”
And it warned prescribers not to prescribe GLP-1 RAs licensed for type 2 diabetes for off-label indications. In July, Novo Nordisk – the manufacturer of several GLP-1 RAs such as liraglutide and semaglutide – said it envisaged intermittent supply until 2025, despite running factories 24/7 to increase production.
If your healthcare provider prescribes Ozempic for weight management, which is an off-label use, insurance isnt as likely to cover it. Restrictions on off-label use: Insurance plans may not cover a medication prescribed off-label , that is, if its not prescribed for its FDA-approved use. affected by a shortage).
On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. Final Guidance at 2.
The second facility for WuXi STA in the US, Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.
It is also often prescribed off-label as a weight loss medication, even in patients with normal blood sugars. For example, its not listed as a side effect in the FDAs 2025 prescribing information. Ozempic is a type of medication called a glucagon-like peptide-1 agonist (GLP-1) and is only given by injection.
The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. billion a 25% gain in the prior year and fuelled in part by extensions to its label to include other progressive ILDs.
After its US approval, analysts at Piper Sandler predicted sales would reach $500 million in 2023, and top $1 billion by 2025, while Jefferies is reckoning on peak sales of $1.5 billion or more.
Mounjaro’s approval in 2022 for T2D has already led to many prescribers providing the therapy off-label to their patients to help them lose weight. Lilly is currently in the midst of initiating a head-to-head Phase IIIb trial for Mounjaro in comparison to Wegovy, which the company expects to conclude in early 2025.
Equalise: making UK immigration costs competitive The UKs visa fees have been labelled as national self-harm by the House of Lords. The country could follow the lead of the EU and Nordic countries by offering alternative pathways for workers to prove their skills. Available from: [link] 2. Internet] UK Parliament.
to fluoride in my tap water, to hidden mold in my home, to my shampoo and deodorant (have you ever read those labels?!), 16] Even more concerning, of the 133 different VOCs found across all tested products, only one, ethanol, was actually listed on any label! From indoor pollutants like formaldehyde (yes, really!),
It will, however, add to BMS’ earnings potential from 2025 – when the company will start to bear the brunt of patent expiries on key drugs, including $12.8 billion product, mainly from first-line use, if it can claim FDA approval for a broad label covering any ROS1-positive cancer.
The 2020–2025 Dietary Guidelines for Americans recommend that Americans limit the amount of sugar they consume to less than 10% of their daily intake of calories. Read food labels carefully. When buying packaged foods, carefully scan the label and look for added sugars. Experts suggest restricting your intake of added sugars.
This is because I had learned about various adulterants found in supplements, how some supplement manufacturers don’t actually put the products that are on the label in the bottle, or that the dosages listed on the label may be completely different from what’s in the products. We have 270 expiring in March 2025.)
One common side effect of Mounjaro is weight loss, which is why it may sometimes be prescribed off-label (for a non-FDA-approved use) for that purpose. But in 2025, people who have Part D will not have to pay more than $2,000 in out-of-pocket costs. This is thanks to a provision in the Inflation Reduction Act of 2022.
Dupixent’s label currently calls for dosing every two weeks for all patients. The company has put tralokinumab at the heart of plans to significantly expand its product sales, R&D pipeline and global presence by 2025. after a lead-in period of dosing every other week. billion in 2020. with #AtopicDermatitis.
The first phaseout milestone is less than a year away; by May 6, 2025 most laboratories will need to demonstrate compliance with Medical Device Reporting (21 C.F.R. § 803), Reporting of Corrections and Removals (21 C.F.R. § 806) and Complaint Files (21 C.F.R. report certain device malfunctions, and.
In 2015, FDA issued a Warning Letter to Kind LLC because, among other things, the company labeled products as healthy whereas these products provided more saturated fat per serving than permitted by the regulatory definition. It is focused on the nutrients in the food product rather than on it overall nutritional “quality.”.
The Federal Register notice states that the Advancing RWE Program “seeks to identify approaches for generating RWE that meet the regulatory requirements in support of labeling for effectiveness ( e.g. , new indications, populations, dosing information) or for meeting post-approval study requirements.”
Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. Otezla was acquired by Amgen for $13.4
Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks. The safety profile in the open-label extension was consistent with the randomised period and with the overall population of patients with IgAN.
Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks. The safety profile in the open-label extension was consistent with the randomised period and with the overall population of patients with IgAN.
Patient safety spotlight: the risks of overprescribing Salbutamol inhalers for asthma [Accessed February 2025]. Accessed February 2025]. Accessed February 2025]. Accessed February 2025]. Accessed February 2025]. Accessed February 2025]. Accessed February 2025]. Accessed February 2025].
This randomised, open label-controlled multicentre clinical trial was conducted across 21 sites in Spain from 2021 to 2023. The study included 92 adult patients with confirmed CDI. Overall, MBK-01 has potential to be an effective, easy-to-administer, low-risk treatment for CDI. References van Prehn J, Reigadas E, Vogelzang EH, et al.
They suggested that pharmacy-specific interventions should include targeted messaging and informative displays at the point of care, clearer labelling on medications to highlight their environmental impact and better access to pharmacy return schemes for unwanted medicines. 2025 Jan 20;15(1):e088066. doi: 10.1136/bmjopen-2024-088066.
Tagrisso meanwhile has been FDA-approved as a second-line treatment for EGFR T790M mutation-positive NSCLC since 2015, with its label extended since then to include first-line and adjuvant treatment. It is AZ’s biggest-selling drug, with sales topping $5 billion last year.
In fact, the priority designation for the final rule is labeled as “economically significant.” Jeff Shuren, director of FDA’s Center for Devices and Radiological Health (CDRH), during his remarks at the annual Food Drug and Law Institute (FDLI) conference in May 2023.
While the FDA sent Lilly a complete response letter detailing issues pertaining to the proposed manufacturing of mirikizumab, the regulator raised no concerns about the clinical data package or label for the medicine. The recent setback dents mirikizumab’s chances to be the first among the IL-23 inhibitors to launch in the US for UC.
Mizuho’s Salim Syed has previously said that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion. Sales of PDE4 inhibitor Otezla grew 13% in the third quarter to $609 million, but analysts have suggested it will come under pressure from deucravacitinib if approved.
The Jardiance drug label lists various warnings about the drug, and certain populations should take it with close oversight from a healthcare professional or avoid taking it altogether. Although there is no generic version of Jardiance available currently, there may be as early as 2025.
As of January 2025, only the Prasco version of dapagliflozin is available in pharmacies. In addition to FDA -approved uses, healthcare providers sometimes prescribe medications for off-label (non- FDA -approved) uses. What are the differences between brand name and generic Farxiga ?
Structure of the eSTAR for De Novos The draft guidance provides a table that offers a high-level overview of the structure of the eSTAR for De Novos, including elements such as the cover letter, device description, proposed indications for use, classification, benefits, risks, mitigation measures, labeling, and supporting data.
Stage 1 is scheduled to take effect on May 6, 2025. FDA plans to hold its next webinar on September 24, 2024, which will cover the labeling requirements that go into effect in Stage 2. See our prior blog post summarizing the different phaseout stages and categories of enforcement discretion.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content